Shots:

•  Nalpropion buys global commercialization rights of Orexigen’s Contrave a weight loss drug. Nalpropion is an investor group which includes Pernix
•  Contrave has approx. 2.5 Mn prescription since 2014- presently- it is launched in 25 countries with expected launch in 13 countries in 2018 and has an US exclusivity till 2030
• Pernix will have an option to acquire either upto 49.9 % of Nalpropion or wholly a special purpose entity

Ref:  Pernixtx | Image: LinkedIn